Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:
Adrienne Matson, PharmD, BCPS–has no relevant financial relationships to disclose in relation to the content of this activity.

Content Development Faculty:
Dara L. Aisner, MD, PhD–has disclosed that she is a consultant for Abbvie and Bristol-Myers Squibb. She also receives grant/research support from Genentech.
Leila Rostamnjad, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Lecia V. Sequist, MD, MPH–has disclosed that she is a consultant for AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Genentech, Merrimack, Novartis, and Pfizer.
Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP–has no relevant financial relationships to disclose in relation to the content of this activity.

Speaking Faculty:
Joshua Bauml, MD–has disclosed that he is a consultant for AstraZeneca, Bristol–Myers Squibb, Boehringer Ingelheim, Celgene, and Clovis. He also receives grant/research support from Bayer, Clovis, Carevive Systems, Janssen, Merck, and Novartis.
David E. Gerber, MD –has disclosed that he is a consultant for AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Celgene, Genentech, Guardant, MS, Peregrine, Samsung, and Synta. He receives grant/research support from AqQule, Boehringer Ingelheim, BerGenBio, Celgene, Genentech, ImmunoGen, Karyopharm, and Peregrine.
Jhanelle E. Gray, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Mark G. Kris, MD, FACP, FACCP–has disclosed that he is a consultant for AstraZeneca.
Heather Wakelee, MD–has disclosed that she is a consultant for ACEA, Genentech, and Novartis. She receives grant/research support from AstraZeneca/Mediummune, Bristol–Myers Squibb, Celgene, Clovis, Exelixix, Genetech/Roche, Gilead, Novartis, Pharmacyclics, Pfizer, and Xcovery.

Peer Reviewers:
Josiah D. Land, PharmD –has no relevant financial relationships to disclose in relation to the content of this activity.
Susan H. Scher, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Elizabeth S. Waxman, RN, MSN, NP-C, AOCN–has no relevant financial relationships to disclose in relation to the content of this activity.